TILZYME is developing the next generation Adoptive Immune Cell Therapy (FucoTILs) that address critical unmet needs for late stage metastatic cancer patients with solid tumors. Our lead clninical initiatives are Human Validation Trial Ready
Targazyme is a holding company with multiple subsidiaries: Our most advanced subsidiaries are StemZyme, developing next generation Transformative Cancer Supportive Care Enzyme medicine TZ 101 (registration trial ready with established human safety and efficacy signal), TILZYME developing the next generation Adoptive Immune Cell Therapy (FucoTILs) that address critical unmet needs for late stage metastatic cancer patients with solid tumors (Human Validation Clinical Trial Ready) and ImmunoZyme developing FucoTregs to address unmet medical needs for potentially life-threatening auto-immune diseases, such as Type 1 Diabetes, and to prevent solid organ transplant rejection (Phase 2 Ready).
Our Adoptive Immune cell therapy products have also been shown in preclinical studies to help turn cold tumors into hot tumors, thereby immune-potentiating products such as checkpoint inhibitors, MABs, growth factors etc. for improved efficacy outcomes for patients as well as enabling market expansion into cold tumor clinical indications.
Our collaborators include Kyowa Hakko Kirin, Vidacord, Resilience, Thermo Fisher, AVID Biosciences, Lonza, The University of Texas MD Anderson Cancer Center, Yale Medical Center, University of Pennsylvania Medical Center, Harvard University Medical Center, Oklahoma Medical Research Foundation, Texas Transplant Institutes, Case Western University Hospitals, Scripps Hospitals, Fred Hutchinson Cancer Research Center, University of California San Diego, Sanford-Burnham Medical Research Institute, NIH/NCI and Indiana University.